Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Corneal refractive surgery to treat refractive errors in adult amblyopic eyes

Search Title by author or title

Session Details

Session Title: Photoablation

Session Date/Time: Tuesday 13/09/2016 | 14:00-16:00

Paper Time: 15:33

Venue: Hall C2

First Author: : L.Mosca ITALY

Co Author(s): :    U. De Vico   L. Guccione   C. Radini   G. Gambini   M. Toro   A. Caporossi     

Abstract Details

Purpose:

To evaluate the safety and efficacy of corneal laser refractive surgery in amblyopic adult eyes.

Setting:

Institute of Ophthalmology, Agostino Gemelli Polyclinic Foundation, Catholic University of Sacro Cuore, Rome, Italy

Methods:

23 eyes of 23 adult patients (range: 24-57yrs) with severe monocular amblyopia were submitted to different laser refractive surgery (PRK, LASEK or LASIK) for the correction of the ametropia. Two patients had strabismic amblyopia, 21 patients had an anisometropic amblyopia. The preoperative and postoperative UCVA and BSCVA were analyzed. Patients were followed up at 1 week, 1 and 3 months.

Results:

The mean preoperative BSCVA was 0.55 (range: 0.2 – 0.8). Three months after surgery 17 patients (74%) experienced one or more lines of BSCVA improvement. The BSCVA was unchanged in 4 eyes (17%) and was worse in 2 eyes (9%). The mean postoperative BSCVA was 0.74 snellen (range: 0.1 - 1.0).

Conclusions:

The laser refractive surgery seems to be safe and more effective than the spectacle or contact lens correction in adult amblyopic eyes. However, despite the little number of patients examined we found a significant increase in visual acuity, such improvement must not be mistaken with the idea of a surgical treatment or a final solution for adult amblyopia.

Financial Disclosure:

NONE

Back to previous